CN

Adverse reaction report

MENU

e1_bannerpc.jpg e1_bannerph.jpg
HOME
NEWS

Company news

20220909-827.jpg

2022.08.25

Saudi SFDA approvals SinoT’s generic drug Posaconazole delayed-release tablets (100mg)

Recently, SinoT’s generic drug Posaconazole delayed-release tablets (100mg) has been approved by Saudi SFDA

Read More

2022.08.25

Saudi SFDA approvals SinoT’s generic drug Posaconazole delayed-release tablets (100mg)

Recently, SinoT’s generic drug Posaconazole delayed-release tablets (100mg) has been approved by Saudi SFDA

Read More

2022.08.25

Saudi SFDA approvals SinoT’s generic drug Posaconazole delayed-release tablets (100mg)

Recently, SinoT’s generic drug Posaconazole delayed-release tablets (100mg) has been approved by Saudi SFDA

Read More

2022.04.07

The generic drug Posaconazole delayed-release tablets (100mg) Regulatory Approval in Singapore

Recently, SinoT’s generic drug Posaconazole delayed-release tablets (100mg) has been granted approval from the Health Sciences Authority (HSA) in Singapore.

Read More

2021.11.02

NMPA approves SinoT’s ANDA application for Bupropion (XL)(150mg,300mg)

Recently, China's National Medical Products Administration (NMPA) approved SinoT’s ANDA application for Bupropion hydrochloride extended-release tablets (XL)(150mg,300mg), this product has already been approved in FDA on August 2017.

Read More

2021.08.12

FDA approves SinoT’s ANDA application for PAROXETINE HYDROCHLORIDE，Extended-Release Tablets

On August 11, 2021，Food and Drug Administration (FDA) approved SinoT’s ANDA（#213612）application for Paroxetine hydrochloride extended-release tablets（12.5mg,25mg）.

Read More

2021.01.26

NMPA approves SinoT's ANDA application for Posaconazole delayed-release tablets (100mg)

Recently, China's National Medical Products Administration (NMPA) approved SinoT’s ANDA application for Posaconazole delayed-release tablets (100mg), this product has already been approved by FDA on August 2019 as the first generic drug.

Read More

2019.08.16

Warmly congratulations to SINOT team for another successfully passing FDA inspection

The US FDA conducted an onsite inspection of our R&D Center located in Shanghai between Aug 12 and Aug 16, 2019.

Read More

Read More

Shanghai Head Office

86 21-6881-9009

Greenland Being Fun Plaza, Bldg. 1, Rm. 207, Pudong New District, Shanghai

Manufacturing Site inJiangsu

86 513-8122-1988

No. 163 Zhuhai Road, Haimen Area, Nantong City, Jiangsu Province

CRO/CDMO Service
News
Products
Lauched Drug
Pending Approvals
ABOUT SINOT
Overview
R&D and Manufacturing
Contact Us
Career
Talent Recruitment
Talent Development and Motivations
Staff activities
Links
Haimen Pharm
Vastpro
D-innovation
qrcode.jpg

Focus on us

Copyright © 2014-2022 SINOTHERAPEUTICS.COM ICP：13048014-1   Powered by Yongsy

Privacy Legal